Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways.

Cancer-induced cachexia, characterized by muscle wasting, is a lethal metabolic syndrome with undefined etiology. Current consensus is that multiple factors contribute to cancer-induced muscle wasting, and therefore therapy requires combinational strategies. Here, we show that Toll-like receptor 4 (TLR4) mediates cancer-induced muscle wasting by directly activating muscle catabolism as well as stimulating an innate immune response in mice bearing Lewis lung carcinoma (LLC), and targeting TLR4 alone effectively abrogate muscle wasting. Utilizing specific siRNAs we observed that LLC cell-conditioned medium (LCM)-treated C2C12 myotubes underwent a rapid catabolic response in a TLR4-dependent manner, including activation of the p38 MAPK-C/EBPβ signaling pathway as well as the ubiquitin-proteasome and autophagy-lysosome pathways, resulting in myotube atrophy. Utilizing a reporter cell-line it was confirmed that LCM activated TLR4. These results suggest that LLC-released cachexins directly activate muscle catabolism via activating TLR4 on muscle cells independent of immune responses. Critically, LLC tumor-bearing TLR4(-/-) mice were spared from muscle wasting due to a blockade in muscle catabolic pathways. Further, tumor-induced elevation of circulating TNFα and interleukin-6 (IL-6) was abolished in TLR4(-/-) mice. These data suggest that TLR4 is a central mediator and therapeutic target of cancer-induced muscle wasting.

Scientific reports. 2017 May 23*** epublish ***

Guohua Zhang, Zhelong Liu, Hui Ding, Hongyu Miao, Jose M Garcia, Yi-Ping Li

Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston (UTHealth), Houston, 77030, Texas, USA., School of Public Health, The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA., Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health Care System, University of Washington, Seattle, 98108, WA, USA., Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston (UTHealth), Houston, 77030, Texas, USA. This email address is being protected from spambots. You need JavaScript enabled to view it..